Inotiv, Inc. Common Stock
NOTVInotiv, Inc. (NOTV) is a contract research organization (CRO) that provides research and development services primarily to biopharmaceutical and biotechnology companies. The company specializes in preclinical research, including pharmacology, toxicology, and ADME (absorption, distribution, metabolism, and excretion) testing, supporting drug discovery and development processes. Inotiv operates laboratories across the United States and offers tailored solutions to accelerate the development of new therapies.
Company News
Inotiv achieved 448% revenue growth from fiscal year 2021 to 2024, ranking 182nd on the Deloitte Technology Fast 500™ list for the third consecutive year, highlighting its strategic expansion and client-focused approach in the contract research organization sector.
Inotiv, Inc. will release its fiscal 2025 fourth quarter and full year financial results on December 3, 2025, after market close, with a conference call to discuss the results at 4:30 p.m. Eastern Time.
Inotiv reported Q3 fiscal 2025 revenue of $130.7 million, a 23.5% increase from the previous year, driven by growth in Research Models and Services. The company reduced its operating loss and received a positive update from the SEC regarding a previous investigation.
Inotiv, Inc. will release its fiscal 2025 third quarter financial results on August 6, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time to discuss the results.
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:
